# Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

> **NCT00005002** · PHASE3 · UNKNOWN · sponsor: **Agouron Pharmaceuticals** · enrollment: 688 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Lamivudine/Zidovudine
- **BIOLOGICAL:** HIV-1 Immunogen
- **DRUG:** Nelfinavir mesylate

## Key facts

- **NCT ID:** NCT00005002
- **Lead sponsor:** Agouron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 688 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005002, "Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00005002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*